|
|
|
|
|
|
|
|
|
29.10.25 - 21:06
|
Guardant Health Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance (Business Wire)
|
|
|
Revenue growth of 39% broadly driven by strong performance across Oncology, Screening, and Biopharma & Data
Raises 2025 revenue guidance to $965 to $970 million, representing year-over-year growth of 31%PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2025.
Third Quarter 2025 Financial Highlights
For the three-month period ended September 30, 2025, as compared to the same period of 2024:
Reported total revenue of $265.2 million, an increase of 39%, driven by:
Oncology revenue of $184.4 million, an increase of 31%, and approximately 74,000 oncology tests, an increase of 40%
Screening revenue of $24.1 million, and approximately 24,000 Shield screening tests, compared to $1.0 million in the prior year period
Biopharma & Data revenue of $54.7 million, an increase of 18%
Generated non-GAAP gross margin of 66%, compared to 63% in the third quarter of 2024
Recent Operating Highlights
...
|
|
|
|
|
26.10.25 - 20:06
|
Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025 (Business Wire)
|
|
|
Expanded cohort reiterates strong adherence rate of over 90% for Shield blood-based colorectal cancer screening test
Survey findings show eligible individuals prefer a blood test for colorectal cancer and lung cancer compared with traditional screening methods
PALO ALTO, Calif.--(BUSINESS WIRE)--$GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data showing the critical role of blood-based testing in increasing cancer screening adherence at the American College of Gastroenterology (ACG) 2025 Annual Meeting in Phoenix, Arizona taking place Friday, October 24 – Wednesday, October 29, 2025.
Building off findings from Guardant Health's 2023 ACG abstract, a study of an expanded cohort of 20,000 patients confirmed findings from earlier reports on the effectiveness of the Shield blood-based screening test in improving adherence to colorectal cancer (CRC) screening. Shield is the first and only blood test to re...
|
|
|
|
|
|
|
09.10.25 - 22:09
|
Guardant Health to Report Third Quarter 2025 Financial Results on October 29, 2025 (Business Wire)
|
|
|
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2025 after market close on Wednesday, October 29, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including...
|
|
|
|
|
|
|
|
|
|
|
|
|
15.09.25 - 22:09
|
Alex M. Azar II Joins Guardant Health Board of Directors (Business Wire)
|
|
|
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Alex M. Azar II to its board of directors, effective immediately. As the 24th Secretary of the U.S. Department of Health and Human Services (HHS), Secretary Azar had oversight and management of agencies critical to all Americans' health care including the Centers for Medicare and Medicaid Services, the Food and Drug Administration, and the Center for Disease Control and Prevention.
“We're honored to welcome Secretary Azar to Guardant's board,” said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. “Secretary Azar has served at the senior-most levels of government as well as the private sector, bringing deep operating experience coupled with a strategic understanding of how policy, innovation and patient access intersect. His perspective will be invaluable as we continue developing new innovations to conquer cancer and working to ensure more patient...
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
